Aquestive Therapeutics (AQST) Cost of Revenue: 2017-2025
Historic Cost of Revenue for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $4.5 million.
- Aquestive Therapeutics' Cost of Revenue rose 1.56% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year decrease of 8.47%. This contributed to the annual value of $17.9 million for FY2024, which is 14.20% down from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Cost of Revenue is $4.5 million, which was down 1.21% from $4.6 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Cost of Revenue ranged from a high of $6.6 million in Q2 2023 and a low of $2.8 million during Q1 2021.
- Its 3-year average for Cost of Revenue is $4.7 million, with a median of $4.5 million in 2024.
- Its Cost of Revenue has fluctuated over the past 5 years, first surged by 57.61% in 2022, then crashed by 31.60% in 2024.
- Quarterly analysis of 5 years shows Aquestive Therapeutics' Cost of Revenue stood at $3.4 million in 2021, then spiked by 57.61% to $5.3 million in 2022, then climbed by 3.34% to $5.5 million in 2023, then fell by 17.55% to $4.5 million in 2024, then climbed by 1.56% to $4.5 million in 2025.
- Its Cost of Revenue was $4.5 million in Q3 2025, compared to $4.6 million in Q2 2025 and $3.7 million in Q1 2025.